Drug intelligence / Profile preview

MQ719

Development stage: Unknown
Lead developer: Memorial Sloan Kettering Cancer Center
Modality: Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intratumoral

Overview

MQ719 is a multi-transgene expressing Modified Vaccinia Virus Ankara-Based Virotherapy. It is currently under investigation in a Phase 1 clinical trial for the treatment of various solid tumor cancers, including melanoma, metastatic cancer, and head and neck squamous cell carcinoma. The drug is administered via intratumoral injection, and its mechanism involves leveraging a modified virus to potentially induce an anti-tumor immune response. It is being studied both as a monotherapy and in combination with pembrolizumab.

Beyond the preview

Go deeper on MQ719.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MQ719.

Explore the full profile